Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05900895 · ClinicalTrials.gov registry record · Phase 1
Estradiol Plus Olaparib for Breast Cancer (PHOEBE)
A Phase 1 study of Metastatic Breast Cancer, sponsored by Mary D Chamberlin.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
- 1
- Study location
NCT05900895: Recruiting Phase 1 study of Metastatic Breast Cancer, sponsored by Mary D Chamberlin.
NCT05900895 is a Phase 1 study of Metastatic Breast Cancer that is actively recruiting participants, run by Mary D Chamberlin. The registered enrollment target is 6 participants, below the 205-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05900895, a Phase 1 study of Metastatic Breast Cancer, is actively recruiting participants, sponsored by Mary D Chamberlin.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
- 1
- Study location
Study Summary
Determine the safety and recommended Phase II dose of olaparib in combination with 17b-estradiol in post-menopausal patients with advanced ER+/HER2- breast cancer.
Primary Outcome
Determine the safety and recommended Phase II dose of olaparib in combination with 17b-estradiol in post-menopausal patients with advanced ER+/HER2- breast cancer.
Conditions Studied
Interventions
- DRUG Olaparib
- DRUG 17b-estradiol
Study Locations (1)
New Hampshire
- Dartmouth Cancer Center - Lebanon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2024-07-15 |
| Est. Completion | 2028-12 |
| Phase | Phase 1 |
What NCT05900895 shows while recruiting
NCT05900895 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 205-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Metastatic Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Olaparib is the first listed.
NCT05900895 reports a single indexed study location in New Hampshire.
Frequently Asked Questions
What is clinical trial NCT05900895 about?
NCT05900895 is a clinical study titled "Estradiol Plus Olaparib for Breast Cancer (PHOEBE)". Determine the safety and recommended Phase II dose of olaparib in combination with 17b-estradiol in post-menopausal patients with advanced ER+/HER2- breast cancer.
What is the current status of trial NCT05900895?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2024-07-15. Estimated completion is 2028-12.
What conditions does trial NCT05900895 study?
This clinical trial studies the following conditions: Metastatic Breast Cancer.
What interventions are being tested in trial NCT05900895?
The interventions under investigation include: Olaparib (DRUG), 17b-estradiol (DRUG).
Who is sponsoring clinical trial NCT05900895?
This trial is sponsored by Mary D Chamberlin, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05900895 being conducted?
This trial has 1 study location across New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05900895's enrollment target sits among peer trials
6 139th of 139 the lowest of 139 other Metastatic Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
RECRUITING · Phase 1
-
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
RECRUITING · Phase 1
-
Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics
RECRUITING · Phase 1
-
Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
RECRUITING · Phase 1
-
PRE-I-SPY Phase I/Ib Oncology Platform Program
RECRUITING · Phase 1
-
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI